Life Sciences Tools and Services
Company Overview of Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC provides contract development and manufacturing services for cell therapy products. The company offers manufacturing solutions; engineering and innovation services; product and process development services; cell and tissue processing; storage, distribution, and delivery of tissues, primary cells, and cell therapy products; and consulting and regulatory support services, such as product and process development, GTP/cGMP manufacturing, regulatory services, and business development and commercialization. It serves academic, biotech, pharmaceutical, and professional clients in the United States. The company was founded in 1997 and is based in Allendale, New Jersey. I...
4 Pearl Court
Allendale, NJ 07401
Founded in 1997
Key Executives for Progenitor Cell Therapy, LLC
President, Chief Scientific Officer and Member of Board Manager
Senior Vice President of Investor Relations
Director of Human Resources
Vice President of Business Development
Compensation as of Fiscal Year 2015.
Progenitor Cell Therapy, LLC Key Developments
Trakcel Ltd. Announce Collaboration Agreement with Caladrius Biosciences, Inc. and its Subsidiary PCT to Drive Cell Therapy Manufacturing Excellence
Jul 28 15
TrakCel Ltd. announced a collaboration agreement with Caladrius Biosciences, Inc. and its subsidiary PCT, a Caladrius Company to implement its cell therapy process management and supply chain integration technology. TrakCel’s technology integrates and automates the entire cell therapy process end-to-end while providing real-time audit logs and chain-of-custody records to stakeholders. It further reduces the implementation risks associated with disparate, paper-based systems as TrakCel technology accelerates scale up and scale out of cell therapy processes through immediate access to data for validation and regulatory audits. PCT and TrakCel will undertake in fourth quarter of 2015 a design specification stage prior to implementing a customized cell therapy process management solution based on TrakCel’s technology. PCT has full-scale cGMP/GLP operations in New Jersey and California, thousands of square feet of Class 10,000 clean rooms, and full QA/QC support. The company has had over 100 clients whose products have treated over 6,000 patients. The collaboration agreement supports UK-based TrakCel’s strategy to expand into the US market, and comes ahead of the company’s plan to establish US offices in 2015.
ImmunoCellular Therapeutics Selects PCT, LLC to Manufacture ICT-107 Immunotherapy for Glioblastoma
Jun 15 15
Caladrius Biosciences (CLBS) announced that its subsidiary, PCT, LLC, has been selected by ImmunoCellular Therapeutics (IMUC) as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with Pct LLC for US Production of ICT-107 for Phase 3 Registration Trial
Jun 15 15
ImmunoCellular Therapeutics Ltd. announced the selection of PCT, LLC as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|